Abstract：Objective: To explore the expression of DJ-1 in prostate cancer and its relationship with curative effect of neoadjuvant endocrine therapy. Methods: The cancer tissues and para-cancerous fresh tissues of 98 patients who were confirmed with prostate cancer by puncture in the hospital from January 2015 to April 2016 were collected. The paraffin blocks of benign prostatic hyperplasia (BPH) tissues from 98 BPH patients were collected. The expression level of DJ-1 protein in each tissue was detected by immunohistochemistry. The expression level of DJ-1 protein in prostate cancer patients before and after neoadjuvant endocrine therapy was detected. χ2 test was applied to analyze the relationship between DJ-1 and clinical pathological parameters of prostate cancer, curative effect of neoadjuvant endocrine therapy. Kaplan-Meier survival curve and Log-rank method were applied to detect the relationship between DJ-1 and biochemical recurrence-free survival (BRFS). Results: The expression level of DJ-1 protein in BPH tissues was significantly lower than that in prostatic cancer tissues (P<0.05). There was no significant difference in the above index between BPH tissues and para-cancerous tissues (P>0.05). The expression level of DJ-1 protein in para-cancerous tissues was significantly lower than that in prostatic cancer tissues (P<0.05). After neoadjuvant endocrine therapy, positive expression of DJ-1 was decreased (P<0.05). There were significant differences in Gleason staging, lymph node metastasis, TNM staging and clinical curative effect between patients with positive DJ-1 and negative DJ-1 (P<0.05). The 3-year BRFS rates in DJ-1 negative (-), weak positive (+), moderate positive (++) and strong positive (+++) group were 93.33%, 87.50%, 74.07% and 70.27%, respectively. The differences among all groups were statistically significant detected by Log-rank test (P<0.05). Conclusion: The expression of DJ-1 is associated with tumor differentiation, lymph node metastasis, TNM staging, clinical curative effect of neoadjuvant endocrine therapy and 3-year BRFS rate, which is of certain predictive value for prognosis of patients with prostate cancer.
韦高猛, 唐毓金, 黄勇平. DJ-1在前列腺癌中的表达及其与新辅助内分泌治疗疗效的关系分析[J]. 河北医学, 2020, 26(10): 1642-1647.
WEI Gaomeng, TANG Yujin, HUANG Yongping. Expression of DJ-1 in Prostate Cancer and its Relationship with Curative Effect of Neoadjuvant Endocrine Therapy. HeBei Med, 2020, 26(10): 1642-1647.
[1] 何乾,张国辉.前列腺肿瘤标志物的研究进展及临床意义[J].癌症进展,2017,15(1):7~9. [2] Goto-Yamaguchi L, Yamamoto-Ibusuki M, Yamamoto Y, et al. Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling[J]. Breast Cancer Research and Treatment, 2018, 172(2):353~362. [3] 师菲,夏术阶.前列腺癌内分泌治疗及其全程管理[J].中国肿瘤生物治疗杂志,2018,25(1):23~27. [4] 高强,张保,史玉强,等.新辅助内分泌治疗后行腹腔镜下前列腺癌根治术治疗局部晚期前列腺癌的临床分析[J].现代泌尿生殖肿瘤杂志,2018,10(3):145~148. [5] 秦露平,吕杰,李名钊,等.68Ga-PSMA-11PET/CT半定量指标对前列腺良恶性病变鉴别诊断的价值[J].中华核医学与分子影像杂志,2019,39(02):67~71. [6] 金晓东,郑锦标.根治性前列腺切除术治疗前列腺癌的相关进展[J].浙江医学,2019,41(24):2567~2570. [7] 王仕钦,江春,黄卫,等.3D腹腔镜下前列腺根治术治疗对前列腺癌患者围术期指标尿控恢复情况及术后并发症的影响[J].河北医学,2019,25(08):1304~1308. [8] Dall'Era M A, Davies B J, Eggener S. Active surveillance for prostate cancer.[J]. European Urology, 2018, 62(6):976~983. [9] 张希,谭国民,廖巾琼,等.低表达DJ-1调控PI3K/AKT通路对肺癌细胞增殖、凋亡的影响[J].现代肿瘤医学,2019,27(12):33~38. [10] 朱小坚,熊文涛,朱正明.DJ-1在消化系统肿瘤中的研究进展[J].中国肿瘤,2018,27(8):608~612.
2020, Vol. 26 
冀公网安备13080202000677号